http://oxfordpharmascience.com/


Oxford Pharmascience is a drug development company that re-develops approved drugs to make them better, safer and easier to take.

Oxford Pharmascience is using its proprietary oral drug delivery technologies to develop improved formulations of non-steroidal anti-inflammatory drugs (NSAIDs) and statins for global markets.

The Company's risk-diversified pipeline of prescription and OTC medicines is focused on cardiovascular disease and pain relief indications. Since the products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market.

The Company has also commercialized calcium/vitamin D chews that taste better and dissolve faster than currently available regular formats. These products are now marketed in the UK, Middle East and Brazil.

Oxford Pharmascience is located in the UK and is led by a highly experienced management team that directs and manages the outsourcing of its development; pre-clinical and clinical programs; and manufacturing to a trusted network of partners and suppliers.

The Company commercializes its portfolio of product opportunities through out-licensing to leading pharmaceutical companies worldwide. Currently the Company has partnerships with Aché Laboratories and Bayer.

Oxford Pharmascience (LON:OXP) was established by a team of entrepreneurs in 2008 and is a publicly listed company on London's Alternative Investment Market (AIM), with a strong blue chip investor base.

investors who participated in the company’s £2mln fund-raising in November at 1.3p a share are sitting on a pretty profit, with the shares currently trading at around 2.2p


Top 10 Emerging Technology Company in 2012
RNS
RNS Number : 0467U
Oxford Pharmascience Group PLC
20 December 2012

Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company")

Named as Top Emerging Technology Company in 2012

Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reformulate medicines, has been featured in Lux Research's "Top Emerging Technology Companies in 2012".

Lux Research profiled 1,380 companies across 15 different emerging technology domains in 2012 and to conclude the year, selected the 10 most compelling companies they had profiled in 2012 across all its coverage areas, with Oxford Pharmascience making the top 10.



Nigel Theobald, CEO, commented:

"It is fantastic to be recognised in this way by such a respected research company as Lux.

We have invested in some exciting technologies for reformulating existing medicines and wholeheartedly agree that through our partnerships with major pharma companies we will indeed have some very compelling products to bring to market "

Moving up well

up 10.5%, Im a 100% upat 2.54p, in at 1.27p

Well done DreamCatcher!

Thanks Toya, OCG going well today as well. Did you grab a few ?

Bought in at 1.27, well up over 100% now, sold half on a free run now.

Time: (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above



Initial formulation development complete
RNS
RNS Number : 4192W
Oxford Pharmascience Group PLC
28 January 2013



Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Oxford Pharmascience completes initial formulation development for leading statins



Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to make medicines better, safer and easier to take, today announces successful completion of formulation development for its Safestat™ formulations of Atorvastatin and Simvastatin, leading generic statin drugs.

The Company has already announced its Safestat™ program which aims to re-formulate the widely used molecules of atorvastatin and simvastatin into doses up to four times lower than the original dose but with the same lipid lowering efficacy as the original higher dose. Global revenue from statins in 2009 was over $27bn despite issues caused by side effects of statins leading to lack of compliance in patients taking these medicines. Safestat™ aims to overcome these issues and increase patient compliance for statins.

The Company has now developed and optimised formulations of both atorvastatin and simvastatin and proven in-vitro release under simulated human conditions.

Marcelo Bravo, Chief Technology Officer of Oxford Pharmascience commented,

"Completion of formulation development is a first important milestone in the Safestat™ programme and we are now ready to proceed to manufacture of GMP products for use in proof of concept clinical trials during 2013."



For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

N+1 Singer

Shaun Dobson/Jenny Wyllie +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The Company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API (active pharmaceutical ingredient).

Oxford Pharmascience Group Plc develops platform technologies that have application across multiple drug categories and can be leveraged across a broad range of reformulation problems. This business model allows us to provide solutions across the industry and fund the ongoing development of cutting edge technologies to better serve the needs of our partners. The partner companies who adopt our technology pay an up-front license fee followed by development milestone payments and then royalties on finished products sold using the technology. OXP invests the upfront licence fee to optimise product development and to ensure seamless technology transfer to the pharmaceutical partner.

House broker N+1 Singer has a positive view on Oxford Pharmascience’s (LON:OXP) pipeline of opportunities, and this morning’s news indicates it is moving ahead on plans to capitalise on those opportunities.

Shares in Oxford Pharmascience shot up 25% today after it successfully completed the formulation development for its Safestat formulations of Atorvastatin and Simvastatin, the leading generic statin drugs.

“Oxford Pharmascience continues to make progress in expanding into the larger generic drugs market, building on its niche position in the over the counter market, and this morning’s news validates this,” the broker said.

“The group was featured in Lux Research’s ‘Top Emerging Technology Companies in 2012’ based on its ability to manipulate properties to improve oral delivery of medicine,” the broker added.

Closed up 26%

Oxford Pharmascience in good heart after passing statin milestone
10:36 am by John Harrington “We’re looking to get into production in 2015," said CEO Nigel Theobald.

If you are one of the many people with high cholesterol who is unable to take medication to lower it because of unpleasant side effects, yesterday’s news from Oxford Pharmascience (LON:OXP) should get the pulse racing.

The group, which specialises in bringing out improved versions of off-patent and soon to be off-patent drugs, has completed the initial formulation development for its versions of generic cholesterol-lowering drugs, Atorvastatin and Simvastatin.

These two leading generic statins are widely prescribed by doctors to patients who have high cholesterol and for whom cholesterol reduction to a desirable level through a change of diet alone is insufficient.

One of the major problems with the statins, though, is that many users suffer unpleasant side effects such as inflammation and muscle damage.

A lower dosage would result in fewer side effects, but also, under normal circumstances, be less effective in lowering the patient’s cholesterol level.

However, Oxford Pharmascience’s Safestat development programme is working on a reformulation of atorvastatin and simvastatin to allow them to be accurately delivered to the colon where they are more effectively absorbed into the liver.

If you want to get “sciency” about it, the new formulation bypasses the gastro-intestinal tract, and this leads to higher levels of the drug reaching the liver, which is where all the cholesterol-inhibiting action goes on.

It’s this by-pass trick which means the same effect can be achieved at around a quarter of the dose, or at least it can under certain laboratory conditions.

As the company announcement put it, Oxford Pharmascience has “proven in-vitro release of its formulations under simulated human conditions.”

The statins market is a huge one, valued at more than US$29bn in 2009, but it could be a lot larger were it not for those pesky side effects.

Nigel Theobald, chief executive officer of Oxford Pharmascience, helpfully gave Proactive Investors an insight into how big the demand could be for its statin products.

“We usually quote figures from www.statinusage.com. Their survey reveals that nearly three-quarters of new users stop taking their statins by the end of the first year of use. Of those, 62% cite side effects as the reason for doing so,” Theobald said.

Oxford Pharmascience’s versions of statins would initially be ideal for “second line intervention” for cholesterol reduction, Theobald explained.

This is when the initial prescription of statins has not worked out, due to the aforementioned side effects.

Monday’s announcement was the first important milestone on the march to market – a march which might not be as long as you would expect, as Theobald explained.

“We’re looking to get into production in 2015. Now, two years might seem like a long time ahead to some, but in the drug development world it is short.

“By working with an existing drug with a proven safety record, we can get it to market a lot quicker and a lot cheaper.”

“We are very happy with the formulations in the lab. The next stage is to move on to manufacture the products to allow us to undertake proof of concept clinical trials this year.”

Theobald stressed that the manufacturing, under good manufacturing practice (GMP) conditions, is just for in-house testing purposes, as the company works to determine what levels of dosage are required to deliver required amounts of the statin to the liver.

Nevertheless, the 26% rise in the share price on Monday to 3.375p indicates that the first hurdle has been successfully negotiated; the shares are up another couple of per cent today.

Further down the road, the company will be looking at the possibility of bringing in a partner to help navigate the path to market.

Going great on this poor market day.

A three bagger at 3.81 :-))

Well done with this one dreamcatcher. I've just bought a few as I think the future is looking good.

up 11%

Thanks d4

http://www.barchart.com/opinions/stocks/OXP.LS&view=detailed

Doesn't get more positive than that - short term/medium term/long term -100% "buy".

Post 17 From Dec -

N+1 Singer sees Oxford Pharmascience (LON:OXP) as an appealing investment case thanks to its diversified technology platforms, strong IP protection and generic drugs dossier ownership.

The broker, which has a target price of 13.41p -

As of Feb 23, 2013, the investment analyst covering Oxford Pharmascience Group Plc advises that the company will outperform the market.


http://markets.ft.com/research/Markets/Tearsheets/Forecasts?s=OXP:LSE

Placing and Notice of General Meeting
RNS
RNS Number : 7271Y
Oxford Pharmascience Group PLC
27 February 2013



Oxford Pharmascience Group plc

("Oxford Pharmascience" or the "Company")



Placing and Notice of General Meeting



Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reposition medicines, announces that it has conditionally raised £5 million (before expenses) through the placing of 166,666,667 New Ordinary Shares at a placing price of 3p per Ordinary Share with discretionary funds managed by Invesco Asset Management Limited. N+1 Singer acted as broker to the Placing.

The placing of these 166,666,667 New Ordinary Shares (the "Placing") is conditional on the Company obtaining approval from Shareholders to their allotment at the General Meeting. The net proceeds of the Placing will be used by the Group to further accelerate the development of the Group's business as described in more detail below.

The circular relating to the Placing (the "Circular") will be posted to shareholders shortly. The Circular contains a notice convening a general meeting of the Company to approve certain matters relating to the Placing. The general meeting of the Company will be held at the offices of Fasken Martineau LLP, Third Floor, 17 Hanover Square, London W1S 1HU at 10.00 am on 19 March 2013.

The Circular will soon be available to view on the Company's website (www.oxfordpharmascience.com). Copies of the Circular will also be available from the registered offices of Oxford Pharmascience at Third Floor, 17 Hanover Square, London, W1S 1HU.

Nigel Theobald, CEO, commented:

"The Company has made strong progress over the past two years in developing and commercialising its innovative technology platforms and recently raised £2 million to strengthen its position for continuing this effort.

We are delighted to have Invesco on board as a major shareholder. This new placement will raise additional funds to allow us to accelerate our work on commercialising our technology platforms and to strengthen our IP position by developing our own dossiers for a range of NSAIDs which we will seek to license to major pharmaceutical companies"

Defined terms are appended to this announcement and have the same meaning as the Circular. The letter from the Chairman to be contained in the Circular is repeated below without material adjustment